Skip to main content
Fig. 5 | Stem Cell Research & Therapy

Fig. 5

From: GATA-targeted compounds modulate cardiac subtype cell differentiation in dual reporter stem cell line

Fig. 5

a Strategy for confirmatory assay for the cardiogenic activity of novel compounds. Compounds were added either prior to (D6–D8, cardiac progenitors) or after (D7–D9, cardiomyocytes) the onset of spontaneous beating in defined, serum-free conditions. b venGFP total fluorescence upon compound treatment with 3i-1000, 3i-1103, and 3i-1047. Cardiac progenitor (CP) and venGFP (Myl2-eGFP, ventricular). Data is presented as mean ± SEM (n = 4, independent experiments). *P < 0.05 (T test vs DMSO control)

Back to article page